Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERA: Estrogen Replacement and Atherosclerosis in Older Women
NCT00000549Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 1994
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of DehydraTECH-estrogen in Coronary atherosclerosis (CAD) (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Minimum diameter of coronary stenotic lesions at 3 years. Started Aug 1994; status: completed.
02
Drugs
DehydraTECH-estrogen
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT00000549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000549.